Funded under the EVI supported AMA1-DiCo project.
Based at: Biomedical Primate Research Centre (BPRC) Rijswijk and Institute of Endemic Diseases, University of Khartoum
Supervisors: Prof. Alan W. Thomas (PhD) and Dr. Bart W. Faber (PhD), BPRC, Rijsvijk
Supervisors: Dr. Ibrahim M. El Hassan (PhD), Institute of Endemic Diseases, University of Khartoum
Development of the Plasmodium knowlesi Rhesus Macaque Model Using the Malaria Vaccine Candidate Apical Membrane Antigen 1 (AMA1) ( University of Khartoum, Sudan, September 2009).
The main objectives of the present study were:
- to produce good quality recombinant apical membrane antigen 1 (AMA1) using Pichia pastoris expression system
- to evaluate the efficacy, immunogenicity, and safety of AMA1 subunit vaccine
- to assess the correlation between antibody titers and protection
- to define the immune responses governing efficacy of Pk4 DNA prime/pox viral boost vaccine and whether it correlates with protection against malaria
- to setup a challenge model to evaluate future malaria vaccine candidates and adjuvants.
Muzamil Mahdi Abdel Hamid was born in Atbara, the northern state, Sudan in 1973. In 1998 he obtained a Bachelor degree in Veterinary Science followed by a Master degree in Molecular Biology in 2002 at the University of Khartoum.
Funded in part by the EVI supported European Malaria Vaccine Development Association (EMVDA) and AMA1-DiCo project.
Based at: Biomedical Primate Research Centre (BPRC) Rijswijk
Promotor: Prof.dr. A.M. Deelder
Co-promotor: Dr. C.H.M. Kocken, BPRC, Rijswijk
Co-promotor: Dr. E.J. Remarque, BPRC, Rijswijk
Towards a blood stage malaria vaccine, dealing with allelic polymorphism in the vaccine candidate apical membrane antigen. 1 (Leiden University, the Netherlands ,January 2012).
This thesis investigated multi-allele vaccine formulation strategies that would overcome the strain-specificity of antibody responses to PfAMA1. The main findings of this thesis are that i) different PfAMA1 alleles share epitopes to which functional cross-strain antibodies can be induced, ii) a three-allele PfAMA1 formulation yields the greatest proportion of functional cross-strain antibodies, and iii) three PfAMA1 alleles, irrespective of the adjuvant used for formulation and whether they are administrated as a multi-allele formulation or sequentially, induce similar proportions of cross-strain antibodies. Overall, a multi-allele formulation with three in silico-designed PfAMA1 candidates yields antibodies that inhibit several parasites in vitro and warrant their development as a human blood stage vaccine.
Kwadwo Asamoah Kusi was born in Accra, Ghana in 1977. In 2005 he obtained a
Masters degree in biochemistry from the University of Ghana, Legon.